Search

Current filters:

Current filters:

Author

Subject

Date issued

Has File(s)

Search Results

Results 1-1 of 1 (Search time: 0.0 seconds).
  • <<
  • 1
  • >>
  • Authors: Andrea, Wolf; Jan A., Stratmann; Shabnam, Shaid;  Advisor: -;  Co-Author: - (2023)

    Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, ICIs have been used clinically since 2015 for patients with advanced/metastatic NSCLC without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) aberrations. As part of I-O Optimise, a multinational research program utilizing real-world data on thoracic malignancies, we describe real-world treatment patterns and survival following reimbursement of ICIs for advanced NSCLC in Germany.